GHRP-6 vs Macimorelin
Research Verdict
Macimorelin is the stronger research reference for the stated comparison criteria. Macimorelin: FDA approved (2017) diagnostic GH secretagogue, Phase 3 validation.
Quick Answers
Which is better, GHRP-6 or Macimorelin?
Macimorelin is the stronger research reference for the stated comparison criteria. Macimorelin: FDA approved (2017) diagnostic GH secretagogue, Phase 3 validation.
What is the key difference between GHRP-6 and Macimorelin?
Macimorelin is oral and single-dose diagnostic; GHRP-6 is injectable, produces appetite stimulation, and is studied for repeated dosing - fundamentally different use contexts despite both being GH secretagogues.
Evidence Comparison
Macimorelin: FDA approved (2017) diagnostic GH secretagogue, Phase 3 validation. GHRP-6: no approval, no FDA-reviewed trials, but decades of published pharmacological characterization. Macimorelin has the regulatory evidence; GHRP-6 has the broader pharmacological literature.
Evidence Context Favoring GHRP-6
Research requiring injectable GH secretagogue with appetite-stimulating properties, or ghrelin receptor pharmacology studies.
Evidence Context Favoring Macimorelin
GH deficiency diagnostic applications, or research needing an FDA-approved secretagogue reference standard.
Side-by-Side Snapshot
| Evidence grade | GHRP-6: Level C Macimorelin: Level A |
|---|---|
| Research status | GHRP-6: Preclinical Macimorelin: FDA Approved |
| Primary category | GHRP-6: Growth Hormone Macimorelin: Growth Hormone |
| Cited studies | GHRP-6: 2 Macimorelin: 2 |